Formulary Search Results for: CALCIUM AND VITAMIN D
5.3.1.5 Other HIV combination preparations - View Category
5.3.1.5 Other HIV combination preparations - View Category
5.3.1.5 Other HIV combination preparations - View Category
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
The use for the treatment of HIV-1 infection in treatment naive adults, or treatment experienced adults without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL, is restricted to HIV specialists only.
5.3.1.5 Other HIV combination preparations - View Category
Restrictions:
- The treatment of HIV infection is restricted to use by HIV specialists.
- Use in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk is restricted to specialist use only by consultants in sexual health and infectious disease consultants.
Prescribing Notes:
Preferred preparation for PrEP in NHSGGC.
Non-Formulary indications:
- Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first-line agents
8.2.5 Immunomodulating drugs used in Multiple Sclerosis - View Category
Restrictions:
Restricted to specialist use for the treatment of relapsing remitting multiple sclerosis in accordance with local guidelines.
8.2.5 Immunomodulating drugs used in Multiple Sclerosis - View Category
Restrictions:
The treatment of adult patients with relapsing remitting multiple sclerosis is restricted to specialist use in accordance with local guidelines.
12.1.2 Otitis media - View Category
Restrictions:
Restricted to use in the treatment of acute otitis media in patients with tympanostomy tubes (AOMT).
9.6.4 Vitamin D - View Category
Prescribing Notes:
Domnisol® is a monthly preparation and could be prescribed for patients where monthly administration would be advantageous. Domnisol® currently is associated with an acquisition cost advantage compared to daily colecalciferol (September 2024).
4.1.1.2 Hypnotics for chronic insomnia - View Category
Restrictions:
Restricted to use in patients where sleep hygiene advice has been unsuccessful and the use of cognitive behavioural therapy for insomnia (CBT-I) has failed or for whom CBT-I is unsuitable or unavailable.
Prescribing Notes:
- For the treatment of adult patients with chronic insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
- Sleepio® is a six-week programme based on CBT-I. Sleepio® is used to treat insomnia and is available free on the NHS. For more information visit Sleep | NHS inform